POCT Creatinine
[POCT Creatinine]
EPTIS Ringversuch Nr. 1144036 | Letze Änderung 2024-05-21 | URL: https://www.eptis.bam.de/pts1144036 https://www.eptis.bam.de/pts1144036
| Name des Anbieters | ||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||
| Ansässig in | United Kingdom | |||||||||
| Sprache(n) | English | |||||||||
| Anmerkungen | Creatinine is a well-established biochemical marker for renal function and is widely used to calculate estimated Glomerular Filtration Rate (eGFR). Whole blood Creatinine meters are increasingly used in Point of Care (POCT) settings such as Radiology as a screen for possible renal dysfunction. This screen is used for the prevention of contrast-induced-nephropathy where administration of nephro-toxic contrast media is required. The programme aim is to cover the clinically relevant ranges, encompassing the cut off for eGFR of 30ml/min/1.73m2. However, the analytical measuring range will also be assessed where appropriate. The programme is suitable for all POCT applications. Three liquid Lysed whole blood samples are distributed bimonthly, with a minimum of 18 samples distributed over the year, covering a wide clinically relevant range. The samples consist of endogenous lysed whole blood samples along with a panel of linearly related samples produced from lysed whole blood spiked with creatinine. They are distributed on a number of occasions over that period, which allows for the assessment of the organisation’s and method’s performance, including linearity, bias, and within and between batch imprecision. Key Features: - Commutable material for whole blood PoCT devices. - Clinically relevant range. - No pre-analytical preparation is required. - Linearly related panel covering the pathological range. For more information: https://www.weqas.com/services/poct-eqa/poct-creatinine/ or contact@weqas.com | |||||||||
| Klassifizierung | ||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||
| Technische Einzelheiten | ||||||||||
|
||||||||||
| Ringversuchsziele | ||||||||||
| Zielgruppe des Ringversuchs | The Programme aims to assess the performance of organisations utilising Point of Care (POCT) Creatinine devices to assess kidney function. | |||||||||
| Relevante Rechtsvorschriften oder Normen | ISO/IEC 17043 | |||||||||
| Weitere Ziele | validation of testing methods | |||||||||
| Teilnehmerzahl | ||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||
| Kosten | ||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
| Regelmässig durchgeführt | Ja (Frequency: Bimonthly. Samples: 3 x 0.5mL) | |||||||||
| Der Ringversuch wird durchgeführt seit | 2013 | |||||||||
| Kontaktdaten des Anbieters | ||||||||||
| Anbieter | Kontaktperson | |||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.